AP2013006742A0 - Combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonsits for treatment of overactive bladder - Google Patents

Combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonsits for treatment of overactive bladder

Info

Publication number
AP2013006742A0
AP2013006742A0 AP2013006742A AP2013006742A AP2013006742A0 AP 2013006742 A0 AP2013006742 A0 AP 2013006742A0 AP 2013006742 A AP2013006742 A AP 2013006742A AP 2013006742 A AP2013006742 A AP 2013006742A AP 2013006742 A0 AP2013006742 A0 AP 2013006742A0
Authority
AP
ARIPO
Prior art keywords
beta
combinations
treatment
antagonsits
overactive bladder
Prior art date
Application number
AP2013006742A
Other languages
English (en)
Inventor
Stephen Caltabiano
Eliot Ohlstein
Stewart Mccallum
Original Assignee
Altherx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2013006742(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altherx Inc filed Critical Altherx Inc
Publication of AP2013006742A0 publication Critical patent/AP2013006742A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2013006742A 2010-08-03 2011-08-02 Combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonsits for treatment of overactive bladder AP2013006742A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37017110P 2010-08-03 2010-08-03
PCT/US2011/046208 WO2012018773A1 (en) 2010-08-03 2011-08-02 Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder

Publications (1)

Publication Number Publication Date
AP2013006742A0 true AP2013006742A0 (en) 2013-02-28

Family

ID=44511540

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2013006742A AP2013006742A0 (en) 2010-08-03 2011-08-02 Combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonsits for treatment of overactive bladder

Country Status (19)

Country Link
US (1) US8642661B2 (es)
EP (1) EP2600859A1 (es)
JP (2) JP2013535486A (es)
KR (2) KR20130135239A (es)
CN (1) CN103269692B (es)
AP (1) AP2013006742A0 (es)
AR (1) AR084122A1 (es)
AU (1) AU2011285928B9 (es)
BR (1) BR112013002511A2 (es)
CA (1) CA2807135C (es)
CL (1) CL2013000342A1 (es)
CO (1) CO6680685A2 (es)
EA (1) EA030145B1 (es)
MX (1) MX353105B (es)
NZ (1) NZ607485A (es)
PE (1) PE20131341A1 (es)
SG (2) SG187689A1 (es)
TW (1) TW201208667A (es)
WO (1) WO2012018773A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016004056A1 (en) * 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US20150306090A1 (en) * 2012-08-31 2015-10-29 Astellas Pharma Inc. Orally administered medical composition
JP2017078023A (ja) * 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
PL3196200T3 (pl) * 2014-08-26 2019-09-30 Astellas Pharma Inc. Pochodne 2-aminotiazolu lub jego sól jako ligandy muskarynowe m3 do leczenia chorób pęcherza moczowego
KR20170086659A (ko) * 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
BR112018007566A2 (pt) * 2015-10-15 2018-10-23 Univ Duke neuromodulação periférica dependente do estado para tratar disfunção da bexiga
US10065922B2 (en) * 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
WO2017210696A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
EP3463307A4 (en) * 2016-06-03 2020-01-15 Velicept Therapeutics, Inc. COMPOSITIONS AND METHODS FOR USE OF SOLABEGRON WITH MODIFIED RELEASE FOR SYMPTOMS OF THE LOWER URINARY PATHWAYS
US20240122958A1 (en) * 2022-10-18 2024-04-18 Bonafide Health, Llc Beta-adrenergic agonist and muscarinic antagonist compositions and methods of using

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (es) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
CZ126598A3 (cs) 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
WO2001054728A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha NOVEL REMEDIES WITH THE USE OF β3 AGONIST
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1682183A2 (de) 2003-11-03 2006-07-26 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
EP1804778A1 (de) * 2004-10-18 2007-07-11 Boehringer Ingelheim International GmbH Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
BRPI0609962B1 (pt) 2005-04-19 2022-01-18 Novartis Ag Composição farmacêutica oral
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US20100113469A1 (en) * 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
PL2216021T3 (pl) 2007-11-02 2013-03-29 Astellas Pharma Inc Kompozycja farmaceutyczna do leczenia zespołu pęcherza nadreaktywnego
CA2719907A1 (en) 2008-04-04 2009-10-08 Merck Sharp & Dohme Corp. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
WO2010118291A2 (en) * 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US8618144B2 (en) 2009-05-08 2013-12-31 Merck Sharp & Dohme Corp Pyrrolidine-derived beta 3 adrenergic receptor agonists
EP2470021B1 (en) 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
IN2012DN00971A (es) 2009-08-27 2015-04-10 Merck Sharp & Dohme
JP5917400B2 (ja) 2009-10-02 2016-05-11 デルタ ティー コーポレーション ファンブレード用のエアフェンス
CA2774992A1 (en) 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト

Also Published As

Publication number Publication date
AU2011285928B2 (en) 2016-06-16
SG10201506076TA (en) 2015-09-29
SG187689A1 (en) 2013-03-28
US20120035118A1 (en) 2012-02-09
EA030145B1 (ru) 2018-06-29
AR084122A1 (es) 2013-04-24
AU2011285928A1 (en) 2013-03-07
CO6680685A2 (es) 2013-05-31
BR112013002511A2 (pt) 2017-06-27
CN103269692B (zh) 2018-02-23
CA2807135A1 (en) 2012-02-09
KR20130135239A (ko) 2013-12-10
NZ607485A (en) 2015-04-24
CA2807135C (en) 2019-05-14
TW201208667A (en) 2012-03-01
PE20131341A1 (es) 2013-12-07
US8642661B2 (en) 2014-02-04
AU2011285928B9 (en) 2018-08-02
WO2012018773A1 (en) 2012-02-09
JP2013535486A (ja) 2013-09-12
EP2600859A1 (en) 2013-06-12
CN103269692A (zh) 2013-08-28
JP2017002074A (ja) 2017-01-05
KR20180008918A (ko) 2018-01-24
MX2013001342A (es) 2013-03-22
MX353105B (es) 2017-12-19
CL2013000342A1 (es) 2013-06-28
JP6441267B2 (ja) 2018-12-19
EA201390066A1 (ru) 2013-07-30

Similar Documents

Publication Publication Date Title
AP2013006742A0 (en) Combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonsits for treatment of overactive bladder
HK1249407A1 (zh) 毒蕈碱受體拮抗劑和β-2腎上腺素受體激動劑的組合
IL225390A0 (en) Polishing pad with multi-modal distribution of pore diameters
EP2841154A4 (en) BLADDER TISSUE MODIFICATION FOR HYPERACTIVE BLADDER TROUBLESHOOTING
EP2680853A4 (en) TREATMENT OF CANCER WITH DOPAMINE RECEPTOR ANTAGONISTS
HK1172602A1 (en) Device for selectively hydrogenating biocompatible solution
ME02297B (me) Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
GB2479213B (en) Pharmaceutical formulations for the treatment of overactive bladder
HK1175698A1 (en) Use of alpha adrenergic receptor agonists for treating or preventing psoriasis
SG10201404909UA (en) Surface Treatments For Alignment Of Block Copolymers
HK1178465A1 (en) Composition for improving condition of skin
EP2265373A4 (en) HYDROGENATION OF IMINES
EP2440081A4 (en) CAPILLARY COMPLEMENT TO CONFER A VOLUMER EFFECT
EP2641560A4 (en) SURGICAL PAD
EP2262795A4 (en) MUSCARIN RECEPTOR AGONISTS, COMPOSITIONS, TREATMENT METHODS ASSOCIATED THEREOF AND METHOD FOR THE PRODUCTION THEREOF
IL215895A0 (en) Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
IL234033A0 (en) Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for the treatment of overactive bladder
HK1174615A1 (en) Ghrelin receptor agonist for treatment of dyscrasia
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
IL217297A0 (en) 5-ht3 receptor modulators, methods of making, and use thereof
ZA201209757B (en) Methods of treating conditions associated with overactive bladder
EP2424540A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF URINARY INCONTINENCE AND ASSOCIATED PATHOLOGIES
GB0914504D0 (en) Use of pre-patinated surfaces for anti-microbial purposes
TWM390142U (en) Massage pad
GB201016836D0 (en) Composition for skin treatment